The company said revenues rose 9.6% to $19.161 billion in Q3 2025, and net income attributable to HCA Healthcare, Inc. increased 29.4% to $1.643 billion ($6.96 per diluted share). Net income attributable to HCA Healthcare, Inc. for Q3 2024 was $1.270 billion.

1. 01

   The company said revenues rose 9.6% to $19.161 billion in Q3 2025, and net income attributable to HCA Healthcare, Inc. increased 29.4% to $1.643 billion ($6.96 per diluted share). Net income attributable to HCA Healthcare, Inc. for Q3 2024 was $1.270 billion.

2. 02

   The company said Adjusted EBITDA for Q3 2025 rose 18.5% to $3.870 billion. Adjusted EBITDA for Q3 2024 was $3.267 billion. Adjusted EBITDA is a non-GAAP measure.

3. 03

   HCA said cash flows from operating activities for Q3 2025 were $4.416 billion ($3.515 billion in Q3 2024). It also said it repurchased 6.514 million shares of common stock for $2.498 billion in the same quarter. The remaining repurchase authorization was $3.256 billion as of September 30, 2025.

4. 04

   HCA updated its full-year 2025 guidance, presenting revenue of $75.000 to $76.500 billion, Adjusted EBITDA of $15.250 to $15.650 billion, and diluted earnings per share of $27.00 to $28.00. The company also declared a quarterly cash dividend of $0.72 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.